FTREHealthcare · BiotechnologyThe 13 Wall Street analysts covering Fortrea Holdings, Inc. hold a median 12-month price target of $24 — +12.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 31 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Fortrea Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (92): Sales and profits are climbing, and climbing faster than before.
Volatility (13): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on FTRE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +12.6% from it.
Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Oct 2026 | UBS | Maintains | Neutral | $22 → $24 |
| 15 Oct 2026 | Deutsche Bank | Upgrade | Buy | $20 → $25 |
| 6 Oct 2026 | Barclays | Upgrade | Overweight | $22 → $23 |
| 6 Oct 2026 | Barclays | Upgrade | Overweight | — |
| 30 Sept 2026 | UBS | Initiates | Neutral | $22 |
| 30 Sept 2026 | UBS | Initiates | Neutral | — |
| 4 Aug 2026 | TD Cowen | Maintains | Buy | $19 → $23 |
| 4 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 31 July 2026 | Citigroup | Maintains | Buy | — |
| 31 July 2026 | Citigroup | Maintains | Buy | $20 → $22 |
| 30 July 2026 | Barclays | Maintains | Equal-Weight | — |
| 30 July 2026 | Barclays | Maintains | Equal-Weight | $18 → $22 |
| 30 July 2026 | Evercore ISI Group | Maintains | Outperform | $20 → $25 |
| 30 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 30 July 2026 | Truist Securities | Maintains | Buy | — |
| 30 July 2026 | Truist Securities | Maintains | Buy | $19 → $26 |
| 13 July 2026 | Mizuho | Maintains | Neutral | $13 → $16 |
| 13 July 2026 | Mizuho | Maintains | Neutral | — |
| 24 June 2026 | Barclays | Maintains | Equal-Weight | — |
| 12 May 2026 | Mizuho | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
FTRE appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Fortrea Holdings, Inc. returned +112.5% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 73% of US stocks
Cheaper than 24% of US stocks
Cheaper than 10% of US stocks
Higher than 25% of US stocks
Higher than 22% of US stocks
Higher than 49% of US stocks
Higher than 27% of US stocks
Higher than 35% of US stocks
Higher than 50% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Fortrea Holdings, Inc. has a market value of $2.0B and an enterprise value of $3.0B.
Revenue in the twelve months to 30 June 2026: $2.7B. The latest quarter shrank 1.4% year on year.
Net income over the same four quarters: −$85.2M, a −3.2% net margin.
Diluted earnings per share, trailing twelve months: $−0.91.
Free cash flow in the twelve months to 30 June 2026: $196.0M, after $31.8M of capital spending.
Trailing P/E: 522.3×; forward P/E: 18.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Fortrea Holdings, Inc. employs 13,871 people — $193K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Fortrea Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Fortrea reported Q3 2026 revenue of $691.5 million, down 1.4% year over year but up 2.0% sequentially. The company cited improving demand, stronger operational execution and continued cost discipline.
Why it matters — FTRE watchers may note the mixed revenue comparisons alongside management’s comments on demand, execution and costs.
The item is a transcript of Fortrea Holdings Inc.’s Q3 2026 earnings call; the excerpt provides no details about the discussion.
Why it matters — FTRE watchers may consult the earnings-call transcript for company commentary, but the provided excerpt contains no substantive results or outlook.
Fortrea Holdings reported quarterly earnings of $0.28 per share, above the Zacks Consensus Estimate of $0.24. Earnings were $0.12 per share in the year-ago quarter.
Why it matters — FTRE watchers may note the company’s reported per-share earnings exceeded the cited consensus estimate and were higher than a year earlier.
Fortrea reported its third-quarter 2026 results, highlighting sustained commercial momentum, continued margin improvement, and targeted investments.
Why it matters — These reported trends may matter to FTRE watchers assessing the company’s growth foundation and operating performance.
Fortrea announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations Tracy Krumme will participate in the Jefferies Global Healthcare Conference.
Why it matters — The conference participation is an investor-relations event that may be of interest to FTRE watchers.
The 13 Wall Street analysts covering Fortrea Holdings, Inc. have a median 12-month price target of $24, with estimates ranging from $14 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Fortrea Holdings, Inc., 7 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Fortrea Holdings, Inc. 93 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Fortrea Holdings, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +12.6% from the last close, and Ticker Nerd's factor model ranks Fortrea Holdings, Inc. 93 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Fortrea Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FTRE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $27 over the next 12 months.
Fortrea Holdings, Inc. returned +112.5% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Fortrea Holdings Inc. is a global contract research organization that provides clinical development solutions to pharmaceutical, biotechnology, and medical device companies.
The most recent item we track (MarketBeat, 29 Oct 2026): "What Fortrea (FTRE) Said on Its Q3 Earnings Call". Fortrea reported Q3 2026 revenue of $691.5 million, down 1.4% year over year but up 2.0% sequentially. The company cited improving demand, stronger operational execution and continued cost discipline.
Fortrea Holdings Inc. is a global contract research organization that provides clinical development solutions to pharmaceutical, biotechnology, and medical device companies. Fortrea Holdings Inc. supports clients across the full clinical trial lifecycle, including Phase I through Phase IV studies, clinical pharmacology, data management, biostatistics, regulatory support, and post-approval evidence services. The company offers flexible delivery models such as full-service, functional service provider, and hybrid arrangements to fit different development needs. Its services are used by biopharma and medtech customers seeking to manage complex trials, improve operational efficiency, and generate the clinical evidence needed to advance products through development and approval. Fortrea Holdings Inc. is headquartered in Durham, North Carolina, and operates as a specialized services provider in the life sciences market.
CEO Mr. Anshul Thakral · 13,871 employees · United States · https://www.fortrea.com
